Grace Therapeutics, Inc GRCE

Healthcare

Grace Therapeutics, Inc., formerly Acasti Pharma Inc., is a late-stage biopharma company with drug candidates addressing rare and orphan diseases. Its therapeutic pipeline consists of three clinical-stage drug candidates supported by an intellectual property portfolio of over 40 granted and pending patents in various jurisdictions. Its lead drug candidate, GTX-104, is a clinical-stage, novel, injectable formulation of nimodipine being developed for intravenous (IV) infusion in aneurysmal subarachnoid hemorrhage (aSAH) patients to address significant unmet medical needs. GTX-104 provides a convenient IV delivery of nimodipine in the intensive care unit, eliminating the need for nasogastric tube administration in unconscious or dysphagic patients. Its other pipeline drug candidates include GTX-102, which is an oral-mucosal betamethasone spray for the treatment of Ataxia Telangiectasia and GTX-101, which is a topical bio adhesive film-forming bupivacaine spray for Postherpetic Neuralgia.

NDAQ:GRCE - Post by User

Grace Therapeutics, Inc > ACST Trading Volume

<< Previous

Bullboard Posts

Next >>

Post by TechOneon Nov 10, 2020 3:24pm

218 Views

Post# 31871838

ACST Trading Volume

12 million shares traded and up 18% on Nasdaq .. On Venture up 26% on average volume..

Not sure what is going on but something is cooking.. 12.3 m shares is a lot for mere speculation..

FWIW

<< Previous

Bullboard Posts

Next >>

Harris or Trump? What scenarios can the TSX expect?